bioRxiv Science⌕ Search

Biology subjects

Lenzi, A.

Publications and source records attributed to Lenzi, A..

2 recordsLinked to original sources

Pde5a Deficiency Prevents Diet-Induced Obesity via Adipose cAMP-PKA Activation Enhancing Fat Browning

Cyclic nucleotides are critical regulators of adaptive thermogenesis and adipogenesis, with their intracellular levels finely tuned by phosphodiesterases. Phosphodiesterase type 5 (PDE5A) modulates cyclic guanosine monophosphate levels in adipocytes. While PDE5A inhibition has shown promise in patients with diabetes, its role in metabolism remains unclear. Using Pde5a knockout mouse models, we demonstrated that mice lacking Pde5a exhibit enhanced browning of white adipose tissue and reduced hepatic fat content. Following high-fat diet, Pde5a-/- mice are resistant to obesity, displaying improved glucose metabolism and enhanced thermogenesis. These protective effects stem from an early developmental knockdown of Pde5a, leading to a metabolic reprogramming driven by cAMP-PKA pathway activation. The convergence of cGMP and cAMP signaling orchestrates thermogenic and systemic metabolic adaptations. Our findings establish PDE5A as a novel regulator of energy homeostasis, suggesting its inhibition as a valuable adjuvant therapy for metabolic disorders.

cell biology↗

AI-driven Classification of Heart Failure Preserved and Reduced Ejection Fraction Patients Using the Total Protein Approach

Heart failure (HF) presents two major subtypes: HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), each one with distinct metabolic characteristics. This study utilized artificial intelligence, high-resolution mass spectrometry and the Total Protein Approach (TPA) to identify key features differentiating these subtypes. Aldolase A (ALDOA), a glycolytic enzyme, was found upregulated in HFrEF patients, reflecting an increased glycolysis pathway, while Arginase 1 (ARG1), a key enzyme in the urea cycle, was also elevated, indicating an increased urea pathway. In contrast, HFpEF patients showed TPA ALDOA and ARG1 levels similar to healthy controls. The combined use of ALDOA and ARG1 TPA values successfully classified 82% of patients (14 out of 17). Additionally, most HFpEF patients were over 80 years old, suggesting an age-related metabolic shift. The combination of ALDOA and ARG1 are promising biomarkers for distinguishing HFpEF and HFrEF using the TPA approach, with potential implications for targeted therapies.

biochemistry↗